Trending...
- Tips for Skin Care During the Winter Months
- Saya International Corporation Announces Appointment of Sheida Chumba to its Board of Directors
- Voyagers Toastmasters Presents How to Conduct a Webinar
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Biogen, Inc. ("Biogen" or the "Company") (NASDAQ: BIIB) investors concerning the Company's possible violations of the federal securities laws.
If you suffered a loss on your Biogen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/biogen-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
Biogen develops therapies for treating neurological and neurodegenerative diseases. One of its product candidates is aducanumab (BIIB037), an investigational human monoclonal antibody studied for use as a treatment for early Alzheimer's disease.
On October 22, 2019, the Company announced that it would seek regulatory approval from the U.S. Food and Drug Administration ("FDA") for aducanumab "based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis." According to Biogen, the new analysis "show[ed] that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing brain amyloid and in reducing clinical decline as assessed by the pre-specified primary endpoint Clinical Dementia Rating-Sum of Boxes (CDR-SB)."
More on The Californer
On November 6, 2020, Reuters reported that an FDA panel found it "cannot ignore unsuccessful trial data on Biogen Alzheimer's drug." The panel had also "voted that an earlier-stage study does not offer supportive evidence of Biogen's application for the drug, aducanumab."
On this news, the Company's stock price fell $92.64 per share, or 28%, to close at $236.26 per share on November 9, 2020, thereby injuring investors.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice: Persons with non-public information regarding Biogen should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About GPM
Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM's attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
More on The Californer
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you suffered a loss on your Biogen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/biogen-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
Biogen develops therapies for treating neurological and neurodegenerative diseases. One of its product candidates is aducanumab (BIIB037), an investigational human monoclonal antibody studied for use as a treatment for early Alzheimer's disease.
On October 22, 2019, the Company announced that it would seek regulatory approval from the U.S. Food and Drug Administration ("FDA") for aducanumab "based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis." According to Biogen, the new analysis "show[ed] that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing brain amyloid and in reducing clinical decline as assessed by the pre-specified primary endpoint Clinical Dementia Rating-Sum of Boxes (CDR-SB)."
More on The Californer
- TripDelivers Announces Delivery Services for Ghost Kitchens USA & Ghost Kitchen Brands of Canada
- Little Sister Entertainment Partners with Doomsday Robot Game Company
- Single Operated Newsletters - The Smartest Entrepreneurs Are Doing This
- Angiocrine Bioscience Announces Oral Presentation of AB-205 Data during the 62nd Annual Meeting of the American Society of Hematology (ASH)
- Stem, Inc. – Market Leader in AI-Driven Clean Energy Storage Systems – to Combine with Star Peak, Creating First Public Pure Play Smart Energy Storage Company
On November 6, 2020, Reuters reported that an FDA panel found it "cannot ignore unsuccessful trial data on Biogen Alzheimer's drug." The panel had also "voted that an earlier-stage study does not offer supportive evidence of Biogen's application for the drug, aducanumab."
On this news, the Company's stock price fell $92.64 per share, or 28%, to close at $236.26 per share on November 9, 2020, thereby injuring investors.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice: Persons with non-public information regarding Biogen should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About GPM
Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM's attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
More on The Californer
- State of Yucatán Ends 2020 with a New International Route
- Long Beach: New Regional Approach to Fight COVID
- Byron Allen To Launch TheGrio.TV As An Over-The-Air Broadcast Television Network And Free Digital Streaming App To Target African-American Viewers
- California: Governor Newsom Statement on Death of San Francisco Sheriff's Deputy 12.3.20
- Christmas Sale On Human Hair Wigs 2020
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The Californer
- Breakthrough Prize Foundation Announces Student Winner of Sixth Annual Breakthrough Junior Challenge
- QSC Expands Surface-Mount Options for AcousticDesign Series Loudspeakers
- Synopsys and Samsung Foundry Collaborate to Deliver Fastest Design Closure and Signoff for Process Nodes Down to 3nm
- Boulevard Partners With Green Circle Salons to Reduce Beauty Industry Waste
- Top Canadian Business Leader Joins CEO Coaching International
- Lumanu Announces Milestone Integration With GRIN
- Canon Medical's Premium Ultrasound Platform Allows for Easy, Fast Scanning with New Advancements
- Centric Software® Pioneers Social PLM
- Coronavirus: Dealing with the "New Normal"
- Buy Xanax 1mg Online | Xanax Bars | No Prescription Needed | tramadolmedication
- Triller and Snoop Dogg Launch New Boxing League Dubbed, "The Fight Club" After Delivering Record-Breaking, Epic Fight Experience with Tyson vs Jones Jr. Event
- Twist Bioscience Announces Pricing of a $300 Million Upsized Public Offering of Common Stock
- CLARA Analytics Unveils Its AI-Based Litigation Avoidance Solution for Commercial Auto
- Shero Comics' Cheerleading Comic, Squad Goals, Debuts as #1 Amazon Best Seller
- California: Governor Newsom Announces Appointments 12.2.20
- San Jose: FLASH REPORT #139 - COVID-19 Response and Recovery
- Quantum Integration's Internet of Things Platform Receives Warm Reception From Early Supporters
- Triumph Tech Achieves AWS DevOps Competency
- Governor Newsom Statement on Death of California Highway Patrol Officer 12.2.20
- Granite Awarded $16 Million Airport Refueling Facility Project in San Diego